164 related articles for article (PubMed ID: 16318423)
1. Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs.
Gelderman KA; Lam S; Gorter A
Expert Opin Biol Ther; 2005 Dec; 5(12):1593-601. PubMed ID: 16318423
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumor outgrowth in a rat colorectal cancer lung metastases model.
Gelderman KA; Kuppen PJ; Okada N; Fleuren GJ; Gorter A
Cancer Res; 2004 Jun; 64(12):4366-72. PubMed ID: 15205353
[TBL] [Abstract][Full Text] [Related]
3. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement.
Blok VT; Daha MR; Tijsma O; Harris CL; Morgan BP; Fleuren GJ; Gorter A
J Immunol; 1998 Apr; 160(7):3437-43. PubMed ID: 9531304
[TBL] [Abstract][Full Text] [Related]
4. Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors.
Fishelson Z; Donin N; Zell S; Schultz S; Kirschfink M
Mol Immunol; 2003 Sep; 40(2-4):109-23. PubMed ID: 12914817
[TBL] [Abstract][Full Text] [Related]
5. Tumor therapy by immune recruitment with bispecific antibodies.
Renner C; Pfreundschuh M
Immunol Rev; 1995 Jun; 145():179-209. PubMed ID: 7590826
[TBL] [Abstract][Full Text] [Related]
6. [The role of membrane glycoproteins CD46, CD55 and CD59 in protection of tumor cells against complement lysis].
Wojnicz D; Bar J; Jankowski S
Postepy Hig Med Dosw; 2002; 56(5):603-16. PubMed ID: 12587428
[TBL] [Abstract][Full Text] [Related]
7. The role of membrane complement regulatory proteins in cancer immunotherapy.
Yan J; Allendorf DJ; Li B; Yan R; Hansen R; Donev R
Adv Exp Med Biol; 2008; 632():159-74. PubMed ID: 19025121
[TBL] [Abstract][Full Text] [Related]
8. The Role of Membrane Bound Complement Regulatory Proteins in Tumor Development and Cancer Immunotherapy.
Geller A; Yan J
Front Immunol; 2019; 10():1074. PubMed ID: 31164885
[TBL] [Abstract][Full Text] [Related]
9. Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces beta-glucan-dependent CR3-dependent cellular cytotoxicity.
Gelderman KA; Lam S; Sier CF; Gorter A
Eur J Immunol; 2006 Apr; 36(4):977-84. PubMed ID: 16525993
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibodies for cancer therapy.
Hollander N
Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
[TBL] [Abstract][Full Text] [Related]
11. T Cell-Redirecting Strategies to 'STAb' Tumors: Beyond CARs and Bispecific Antibodies.
Blanco B; Compte M; Lykkemark S; Sanz L; Alvarez-Vallina L
Trends Immunol; 2019 Mar; 40(3):243-257. PubMed ID: 30827461
[TBL] [Abstract][Full Text] [Related]
12. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
van Ravenswaay Claasen HH; Eggermont AM; Nooyen YA; Warnaar SO; Fieuren GJ
Gynecol Oncol; 1994 Feb; 52(2):199-206. PubMed ID: 8314139
[TBL] [Abstract][Full Text] [Related]
14. Bi-specific antibody therapy for the treatment of cancer.
Withoff S; Helfrich W; de Leij LF; Molema G
Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
[TBL] [Abstract][Full Text] [Related]
15. ImmTACs for targeted cancer therapy: Why, what, how, and which.
Oates J; Hassan NJ; Jakobsen BK
Mol Immunol; 2015 Oct; 67(2 Pt A):67-74. PubMed ID: 25708206
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies.
Taylor RP; Lindorfer MA
Semin Immunol; 2016 Jun; 28(3):309-16. PubMed ID: 27009480
[TBL] [Abstract][Full Text] [Related]
17. Tumor-antigen-binding bispecific antibodies for cancer treatment.
Weidle UH; Kontermann RE; Brinkmann U
Semin Oncol; 2014 Oct; 41(5):653-60. PubMed ID: 25440609
[TBL] [Abstract][Full Text] [Related]
18. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
19. Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
Haagen IA
Leuk Lymphoma; 1995 Nov; 19(5-6):381-93. PubMed ID: 8590837
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells.
Russoniello C; Somasundaram C; Schlom J; Deo YM; Keler T
Clin Cancer Res; 1998 Sep; 4(9):2237-43. PubMed ID: 9748144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
